Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin plus gemcitabine/nab-paclitaxel in advanced pancreatic cancer (T-CORE2201)
jRCTs021230005Phase 2Recruiting
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of levofloxacin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Progression-free survival. Started Jun 2023; status: recruiting.
02
Drugs
levofloxacin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs021230005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021230005.